Cover Image

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor

Abstract Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents. Venetoclax pharmacokinetics has been extensively characterized in patients and healthy participants. After oral dosing, the media...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ahmed Hamed Salem (Author), Rajeev M. Menon (Author)
Format:	Book
Published:	Wiley, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
by: Ali A. Alhadab, et al.
Published: (2020)

A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold‐labeled venetoclax, from chemistry to the clinic
by: Amr Alaarg, et al.
Published: (2022)

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
by: Nimita Dave, et al.
Published: (2019)

Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
by: Robin J. Svensson, et al.
Published: (2023)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
by: Persson PB
Published: (2015)

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review
by: Zhao Y, et al.
Published: (2024)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
by: Qiang Cao, et al.
Published: (2023)

Pre-Clinical Pharmacokinetic and Pharmacodynamic Characterization of Selected Chiral Flavonoids: Pinocembrin and Pinostrobin
by: Casey L. Sayre, et al.
Published: (2015)

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
by: Shen Z, et al.
Published: (2015)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
by: Qingfang Li, et al.
Published: (2019)

A comprehensive review of the pharmacodynamics, pharmacokinetics and clinical effects of the neutral endopeptidase inhibitor racecadotril
by: Marion eEberlin, et al.
Published: (2012)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
by: Shen Z, et al.
Published: (2017)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
by: Atsuo Tahara, et al.
Published: (2016)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions
by: Johanna Weiss, et al.
Published: (2016)

PP 8.9 - 00142 Safety and activity of BCL-2 inhibitor Venetoclax in uninfected rhesus macaques
by: T. Wiche Salinas, et al.
Published: (2022)

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)
by: Dipti Pawaskar, et al.
Published: (2022)

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
by: Hidetoshi Shimizu, et al.
Published: (2024)

Pharmacodynamics of Rivaroxaban and Dabigatran in Adults with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
by: Teerachat Punnachet, et al.
Published: (2024)

Synergistic effect of venetoclax and teglicar in multiple myeloma cell lines
by: Belal A. Al-Husein, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
by: Hall J, et al.
Published: (2018)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
by: Tingting Ma, et al.
Published: (2022)

Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor
by: Phyllis Chan, et al.
Published: (2021)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017)

Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
by: Julia Koch-Heier, et al.
Published: (2022)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
by: Kim CO, et al.
Published: (2016)

Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
by: Miro Julian Eigenmann, et al.
Published: (2021)

The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses
by: Yuanxun Yang, et al.
Published: (2024)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020)

Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus
by: Yusuke Tadayasu, et al.
Published: (2013)

LC-MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study
by: Abdulaziz I. Alnasser, et al.
Published: (2023)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
by: Susanna Burckhardt, et al.
Published: (2011)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
by: Hirsh Elhence, et al.
Published: (2022)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
by: Roganović Maša, et al.
Published: (2021)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
by: Andrew A Voak, et al.
Published: (2021)

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
by: Qing Ling, et al.
Published: (2023)

Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
by: Reisman SA, et al.
Published: (2019)